JP2016539149A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539149A5 JP2016539149A5 JP2016536539A JP2016536539A JP2016539149A5 JP 2016539149 A5 JP2016539149 A5 JP 2016539149A5 JP 2016536539 A JP2016536539 A JP 2016536539A JP 2016536539 A JP2016536539 A JP 2016536539A JP 2016539149 A5 JP2016539149 A5 JP 2016539149A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- compound
- acceptable salt
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 238000004820 blood count Methods 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000000144 pharmacologic effect Effects 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010048610 Cardiotoxicity Diseases 0.000 claims 1
- 208000034656 Contusions Diseases 0.000 claims 1
- 208000012609 Cowden disease Diseases 0.000 claims 1
- 201000002847 Cowden syndrome Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033733 Papule Diseases 0.000 claims 1
- 206010034972 Photosensitivity reaction Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000025371 Taste disease Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000034526 bruise Diseases 0.000 claims 1
- 231100000259 cardiotoxicity Toxicity 0.000 claims 1
- 201000002758 colorectal adenoma Diseases 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000005976 liver dysfunction Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 201000000235 ovarian squamous cell carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000036211 photosensitivity Effects 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 201000010700 sporadic breast cancer Diseases 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 235000019669 taste disorders Nutrition 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306679.5 | 2013-12-06 | ||
| EP13306679 | 2013-12-06 | ||
| PCT/IB2014/066558 WO2015083101A1 (en) | 2013-12-06 | 2014-12-03 | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016539149A JP2016539149A (ja) | 2016-12-15 |
| JP2016539149A5 true JP2016539149A5 (enExample) | 2017-12-28 |
Family
ID=49876516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536539A Pending JP2016539149A (ja) | 2013-12-06 | 2014-12-03 | アルファ−アイソフォーム選択的ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20170000778A1 (enExample) |
| EP (2) | EP3076969B1 (enExample) |
| JP (1) | JP2016539149A (enExample) |
| KR (1) | KR20160095035A (enExample) |
| CN (1) | CN105979947A (enExample) |
| AU (2) | AU2014358773A1 (enExample) |
| BR (1) | BR112016011811A2 (enExample) |
| CA (1) | CA2930359C (enExample) |
| CL (1) | CL2016001361A1 (enExample) |
| DK (1) | DK3076969T3 (enExample) |
| ES (1) | ES2899167T3 (enExample) |
| HU (1) | HUE057092T2 (enExample) |
| IL (1) | IL245709B (enExample) |
| MX (1) | MX378409B (enExample) |
| PH (1) | PH12016501026A1 (enExample) |
| PL (1) | PL3076969T3 (enExample) |
| PT (1) | PT3076969T (enExample) |
| RU (1) | RU2680246C1 (enExample) |
| SI (1) | SI3076969T1 (enExample) |
| TN (1) | TN2016000179A1 (enExample) |
| TW (1) | TWI666019B (enExample) |
| WO (1) | WO2015083101A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017077445A1 (en) * | 2015-11-02 | 2017-05-11 | Novartis Ag | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor |
| WO2018060833A1 (en) * | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
| GB202010627D0 (en) * | 2020-07-10 | 2020-08-26 | Qbd (Qs-Ip) Ltd | Blocking method |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US4323581A (en) | 1978-07-31 | 1982-04-06 | Johnson & Johnson | Method of treating carcinogenesis |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| WO1988007045A1 (fr) | 1987-03-09 | 1988-09-22 | Kyowa Hakko Kogyo Co., Ltd. | Derives de la substance physiologiquement active k-252 |
| US4904768A (en) | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
| WO1989007105A1 (fr) | 1988-02-04 | 1989-08-10 | Kyowa Hakko Kogyo Co., Ltd. | Derives de staurosporine |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| EP0540185A1 (en) | 1991-10-10 | 1993-05-05 | Schering Corporation | 4'-(N-substituted-N-oxide)staurosporine derivatives |
| US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| JPH07505124A (ja) | 1991-11-08 | 1995-06-08 | ザ ユニバーシティ オブ サザン カリフォルニア | ニューロトロフィン活性増強のためのｋ−２５２化合物を含む組成物 |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| US5948898A (en) | 1992-03-16 | 1999-09-07 | Isis Pharmaceuticals, Inc. | Methoxyethoxy oligonucleotides for modulation of protein kinase C expression |
| US5621100A (en) | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | K-252a derivatives for treatment of neurological disorders |
| US5756494A (en) | 1992-07-24 | 1998-05-26 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
| FI950887A0 (fi) | 1992-08-31 | 1995-02-27 | Ludwig Inst Cancer Res | MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt |
| EP0630898B1 (en) | 1992-09-21 | 2001-11-28 | Kyowa Hakko Kogyo Co., Ltd. | Thrombocytopenia remedy |
| HU221343B1 (en) | 1992-10-28 | 2002-09-28 | Genentech Inc | Use of anti-vegf antibodies for the treatment of cancer |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| CZ288182B6 (en) | 1993-07-15 | 2001-05-16 | Minnesota Mining & Mfg | Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon |
| US5478932A (en) | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
| CA2179650C (en) | 1993-12-23 | 2007-10-30 | William Francis Heath, Jr. | Bisindolemaleimides and their use as protein kinase c inhibitors |
| US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| DE122005000053I2 (de) | 1995-03-30 | 2008-01-17 | Pfizer Prod Inc | Chinazolinderivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| AU6888196A (en) | 1995-08-11 | 1997-03-12 | Yale University | Glycosylated indolocarbazole synthesis |
| FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| HU221227B1 (en) | 1995-12-08 | 2002-08-28 | Janssen Pharmaceutica Nv | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives, their preparation, pharmaceutical compositions containing them and their use |
| KR100447918B1 (ko) | 1996-07-25 | 2005-09-28 | 동아제약주식회사 | 대장을포함한위장관보호작용을갖는플라본및플라바논화합물 |
| JP4301576B2 (ja) | 1996-08-02 | 2009-07-22 | ローラス セラピューティクス インコーポレイテッド | リボヌクレオチドレダクターゼのｒ１およびｒ２成分に対して指向される抗腫瘍アンチセンス配列 |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
| DE69832715T2 (de) | 1997-07-12 | 2007-01-11 | Cancer Research Technology Ltd. | Cyclin-abhängige-kinase inhibierende purinderivate |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| CN1250526C (zh) | 1998-05-29 | 2006-04-12 | 苏根公司 | 吡咯取代的2－吲哚满酮蛋白激酶抑制剂 |
| US20030083242A1 (en) | 1998-11-06 | 2003-05-01 | Alphonse Galdes | Methods and compositions for treating or preventing peripheral neuropathies |
| HU226742B1 (en) | 1999-06-25 | 2009-08-28 | Genentech Inc | Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies |
| WO2001004125A1 (en) | 1999-07-13 | 2001-01-18 | Kyowa Hakko Kogyo Co., Ltd. | Staurosporin derivatives |
| UA72946C2 (uk) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
| CA2696185C (en) * | 1999-12-06 | 2014-09-23 | Geistlich Pharma Ag | Use of taurolidine and derivatives thereof in the treatment of cancer by induction of apoptosis |
| CN1329390C (zh) | 2000-02-15 | 2007-08-01 | 苏根公司 | 吡咯取代的2－二氢吲哚酮蛋白激酶抑制剂 |
| JP2003531148A (ja) | 2000-04-12 | 2003-10-21 | ジェネーラ・コーポレーション | 保護されていない７−α−ヒドロキシ基を有する中間体を使用する、７−α−ヒドロキシ３−アミノ置換ステロイドの調製のためのプロセス |
| AU7307101A (en) | 2000-06-30 | 2002-01-14 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
| WO2002022598A1 (en) | 2000-09-11 | 2002-03-21 | Chiron Corporation | Quinolinone derivatives as tyrosine kinase inhibitors |
| US6677450B2 (en) | 2000-10-06 | 2004-01-13 | Bristol-Myers Squibb Company | Topoisomerase inhibitors |
| CA2434802C (en) | 2001-01-16 | 2013-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
| WO2002062826A1 (fr) | 2001-02-07 | 2002-08-15 | Vadim Viktorovich Novikov | Procede de fabrication des peptides |
| US20040186172A1 (en) | 2001-07-02 | 2004-09-23 | Houssam Ibrahim | Oxaliplatin active substance with a very low content of oxalic acid |
| KR100484504B1 (ko) | 2001-09-18 | 2005-04-20 | 학교법인 포항공과대학교 | 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물 |
| US20030134846A1 (en) | 2001-10-09 | 2003-07-17 | Schering Corporation | Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors |
| WO2003077902A1 (en) | 2002-02-19 | 2003-09-25 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| EA007987B1 (ru) | 2002-03-29 | 2007-02-27 | Чирон Корпорейшн | Замещённые бензазолы и их применение в качестве ингибиторов киназы raf |
| US6727272B1 (en) | 2002-07-15 | 2004-04-27 | Unitech Pharmaceuticals, Inc. | Leflunomide analogs for treating rheumatoid arthritis |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| CA2511646A1 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
| WO2004064759A2 (en) | 2003-01-21 | 2004-08-05 | Chiron Corporation | Use of tryptanthrin compounds for immune potentiation |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| SI3248600T1 (sl) * | 2005-02-18 | 2020-09-30 | Abraxis Bioscience, Llc | Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| RU2589695C2 (ru) * | 2010-11-08 | 2016-07-10 | Новартис Аг | Использование производных 2-карбоксамид-циклоамино мочевины в лечении egfr-зависимых заболеваний или заболеваний с приобретенной резистентностью к агентам, нацеленным на члены egfr-семейства |
| KR20140033432A (ko) * | 2011-06-21 | 2014-03-18 | 노파르티스 아게 | (s)-피롤리딘-1,2-디카르복실산 2-아미드 1-(｛4-메틸-5-[2-(2,2,2-트리플루오로-1,1-디메틸-에틸)-피리딘-4-일]-티아졸-2-일｝-아미드)의 다형체 |
| EP2601965A1 (en) * | 2011-12-06 | 2013-06-12 | Apeiron Biologics AG | Compositions for preventing or treating adverse reactions of EGFR inhibition |
| SG10201608469RA (en) | 2012-05-16 | 2016-11-29 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
-
2014
- 2014-12-03 DK DK14812658.4T patent/DK3076969T3/da active
- 2014-12-03 AU AU2014358773A patent/AU2014358773A1/en not_active Abandoned
- 2014-12-03 PL PL14812658T patent/PL3076969T3/pl unknown
- 2014-12-03 SI SI201431901T patent/SI3076969T1/sl unknown
- 2014-12-03 EP EP14812658.4A patent/EP3076969B1/en not_active Revoked
- 2014-12-03 KR KR1020167017707A patent/KR20160095035A/ko not_active Ceased
- 2014-12-03 PT PT148126584T patent/PT3076969T/pt unknown
- 2014-12-03 CA CA2930359A patent/CA2930359C/en active Active
- 2014-12-03 BR BR112016011811A patent/BR112016011811A2/pt not_active Application Discontinuation
- 2014-12-03 HU HUE14812658A patent/HUE057092T2/hu unknown
- 2014-12-03 WO PCT/IB2014/066558 patent/WO2015083101A1/en not_active Ceased
- 2014-12-03 MX MX2016007376A patent/MX378409B/es unknown
- 2014-12-03 EP EP21193406.2A patent/EP4000619A1/en not_active Withdrawn
- 2014-12-03 JP JP2016536539A patent/JP2016539149A/ja active Pending
- 2014-12-03 CN CN201480074816.7A patent/CN105979947A/zh active Pending
- 2014-12-03 RU RU2016126716A patent/RU2680246C1/ru active
- 2014-12-03 ES ES14812658T patent/ES2899167T3/es active Active
- 2014-12-03 US US15/101,155 patent/US20170000778A1/en not_active Abandoned
- 2014-12-03 TN TN2016000179A patent/TN2016000179A1/en unknown
- 2014-12-05 TW TW103142503A patent/TWI666019B/zh not_active IP Right Cessation
-
2016
- 2016-05-18 IL IL245709A patent/IL245709B/en active IP Right Grant
- 2016-05-31 PH PH12016501026A patent/PH12016501026A1/en unknown
- 2016-06-03 CL CL2016001361A patent/CL2016001361A1/es unknown
-
2017
- 2017-09-29 US US15/719,636 patent/US10434092B2/en not_active Expired - Fee Related
- 2017-10-09 AU AU2017245292A patent/AU2017245292B2/en not_active Ceased
-
2019
- 2019-08-29 US US16/556,111 patent/US20200069670A1/en not_active Abandoned
-
2020
- 2020-11-25 US US17/105,453 patent/US20210196696A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2576289T3 (es) | Nanopartículas de paclitaxel y albúmina en combinación con bevacizumab contra el cáncer | |
| JP2022009090A5 (enExample) | ||
| JP2016006096A5 (enExample) | ||
| JP2009514874A5 (enExample) | ||
| RU2019133284A (ru) | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства | |
| JP2016528162A5 (enExample) | ||
| JP2014512356A5 (enExample) | ||
| CN104436194B (zh) | 具有协同增效作用的抗癌组合物 | |
| JP2013509411A5 (enExample) | ||
| JP2016515628A5 (enExample) | ||
| JP6855488B2 (ja) | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット | |
| JP2015517523A5 (enExample) | ||
| JP2012522837A5 (enExample) | ||
| JP2023102786A5 (enExample) | ||
| CN103533940A (zh) | 治疗晚期实体瘤的方法 | |
| JP2021509395A5 (enExample) | ||
| JP2016539149A5 (enExample) | ||
| CN101939001B (zh) | 用于治疗卵巢癌的含有紫杉醇的组合 | |
| JP2018522028A5 (enExample) | ||
| JP2019218379A5 (enExample) | ||
| JP2008536853A5 (enExample) | ||
| JP2016507500A5 (enExample) | ||
| JP2020515523A5 (enExample) | ||
| JP2015507020A5 (enExample) | ||
| CN1511036A (zh) | 包含信号转导抑制剂和埃坡霉素衍生物的联合形式 |